<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(AMENDMENT NO. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 14, 1998
MICROCIDE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 0-28006 94-3186021
-------- ------- ----------
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification Number)
</TABLE>
850 Maude Avenue
Mountain View, CA 94043
(Address of Principal Executive Offices)
(650) 428-1550
(Registrant's Telephone Number, Including Area Code)
<PAGE> 2
EXPLANATORY NOTE
The undersigned Registrant hereby amends item 7(b) of its Form 8-K
originally filed with the Securities and Exchange Commission on January 29, 1998
to provide the financial statements required by Article 11 of Regulations S-X.
Item 7 FINANCIAL STATEMENTS AND EXHIBITS.
(b) Pro Forma Financial Information.
The financial statements required by Article 11 of Regulation
S-X are expected to be filed by the Registrant within sixty (60) days of the
date of this Report.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MICROCIDE PHARMACEUTIALS, INC.
Dated: January 30, 1998 By: /s/ MATTHEW J. HOGAN
---------------------------
Matthew J. Hogan
Chief Financial Officer
(principal financial and
accounting officer)
